Banco Santander S.A. Has $44.45 Million Stock Holdings in Bristol Myers Squibb Company $BMY

Banco Santander S.A. lifted its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 63.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 824,062 shares of the biopharmaceutical company’s stock after purchasing an additional 320,137 shares during the quarter. Banco Santander S.A.’s holdings in Bristol Myers Squibb were worth $44,450,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Wealthspire Advisors LLC boosted its position in shares of Bristol Myers Squibb by 57.9% during the fourth quarter. Wealthspire Advisors LLC now owns 40,617 shares of the biopharmaceutical company’s stock worth $2,191,000 after buying an additional 14,898 shares during the period. Tiemann Investment Advisors LLC acquired a new position in shares of Bristol Myers Squibb during the fourth quarter worth about $205,000. Allianz SE boosted its position in shares of Bristol Myers Squibb by 10.4% during the fourth quarter. Allianz SE now owns 103,850 shares of the biopharmaceutical company’s stock worth $5,602,000 after buying an additional 9,817 shares during the period. Macquarie Group Ltd. boosted its position in shares of Bristol Myers Squibb by 2.0% during the fourth quarter. Macquarie Group Ltd. now owns 2,016,204 shares of the biopharmaceutical company’s stock worth $108,700,000 after buying an additional 39,889 shares during the period. Finally, Summit Financial LLC boosted its position in shares of Bristol Myers Squibb by 11.6% during the fourth quarter. Summit Financial LLC now owns 72,151 shares of the biopharmaceutical company’s stock worth $3,892,000 after buying an additional 7,498 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Trading Up 0.3%

Shares of Bristol Myers Squibb stock opened at $57.05 on Friday. The business has a fifty day simple moving average of $57.73 and a two-hundred day simple moving average of $56.87. The company has a market capitalization of $116.49 billion, a price-to-earnings ratio of 16.02, a P/E/G ratio of 0.16 and a beta of 0.24. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The business had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. During the same period in the previous year, the company posted $1.80 EPS. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts forecast that Bristol Myers Squibb Company will post 6.32 EPS for the current year.

Analysts Set New Price Targets

BMY has been the subject of several recent research reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Wall Street Zen cut Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 6th. Bank of America reduced their price objective on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a research note on Thursday, April 9th. HSBC increased their price objective on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research note on Tuesday, March 17th. Finally, Royal Bank Of Canada initiated coverage on Bristol Myers Squibb in a research report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price target for the company. Eight investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $61.31.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Analyst commentary highlighted that BMY’s growth portfolio now generates more than half of revenue, with Reblozyl, Breyanzi and Cobenfy delivering strong gains that help balance declines in legacy products. Article Title
• Positive Sentiment: Bristol Myers Squibb advanced its Phase 1 liver study for BMS-986435, adding another pipeline update that supports long-term growth prospects. Article Title
• Positive Sentiment: The company also reported momentum in its mavacamten heart-drug franchise, with a real-world study signaling continued traction in the cardiovascular market. Article Title
• Neutral Sentiment: Bristol Myers is rolling out an AI-driven procurement overhaul and expanding an oncology collaboration with Arcus Biosciences, which could improve efficiency and bolster its cancer pipeline over time. Article Title
• Neutral Sentiment: Erste Group made only small tweaks to earnings estimates, leaving FY2026 in line with consensus and slightly trimming FY2027, a mixed signal that does not materially change the near-term outlook. Article Title
• Negative Sentiment: Takeda said its AI-designed psoriasis pill beat Bristol Myers’ Sotyktu in a head-to-head trial, raising competitive concerns for one of BMY’s dermatology assets. Article Title

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.